NextCure reports positive SIM0505 trial data for gynecologic cancers
Tweet Send to a Friend
NextCure Inc. (NASDAQ: NXTC) and Simcere Zaiming Pharmaceutical Co. Ltd. announced positive Phase 1 dose escalation data for SIM0505, an ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
